Phase IB study of pembrolizumab (Pembro) and pegylated-interferon alfa-2b (Peg-IFN) in advanced melanoma (MEL).
Diwakar Davar(University of Pittsburgh), Giuseppe Lo Russo(Fondazione IRCCS Istituto Nazionale dei Tumori), Joë-Marc Chauvin(University of Pittsburgh), Julien Fourcade(University of Pittsburgh), Ahmad A. Tarhini(UPMC Hillman Cancer Center), Ornella Pagliano(University of Pittsburgh Medical Center), Hassane M. Zarour(University of Pittsburgh), Nageatte Ibrahim(Merck & Co., Inc., Rahway, NJ, USA (United States)), Carrie Muniz(University of Pittsburgh Medical Center), Hussein Tawbi(University of Pittsburgh), Zhaojun Sun(University of Pittsburgh), Cindy Sander(University of Pittsburgh Medical Center), Hong Wang(Zhejiang University of Technology), Uma N. M. Rao(University of Pittsburgh Medical Center), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Amy Rose(University of Pittsburgh Medical Center), John M. Kirkwood(UPMC Hillman Cancer Center)
Cited by 2
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k